中國綠島科技(02023.HK)擬5655萬元收購聯營公司82%股權
格隆匯 4 月 19日丨中國綠島科技(02023.HK)發佈公吿,2020年10月10日,買方(浙江綠島科技有限公司,公司的間接全資附屬公司)與賣方(即台州青喚貿易有限公司)訂立收購協議,據此,根據收購協議的條款及條件,賣方已同意出售目標公司(即國藥景嶽氣霧劑有限公司)82%股權,現金代價為人民幣5655萬元。完成已於簽訂收購協議時進行。
目標公司為一間於中國成立的有限公司,連同其附屬公司主要從事研究及開發、製造及銷售醫用及食用氣霧劑產品項目的投資及開發。緊接收購事項完成前,集團透過買方持有目標公司的7%股權。完成後,目標公司由買方擁有89%權益及由兩名獨立第三方擁有11%權益。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.